


## About Olympus Europa

Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people's lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries.

Olympus Europa, headquartered in Hamburg, Germany, serves the EMEA (Europe, Middle East, Africa) region and employs more than 7,800 people in 21 countries. For more information, visit [www.olympus-europa.com](http://www.olympus-europa.com).


### Global Revenue by Business Divisions<sup>1</sup>



■ Others

\*Life Science Solutions and Industrial Solutions are being operated by Evident Corporation as of April 1<sup>st</sup>, 2022.

### Global Revenue by Region<sup>1</sup>



**TOP 100**

Since 2012 to 2020, and in 2022, Olympus has been awarded as one of the top 100 most innovative companies in the world.<sup>3</sup>

Since 1966, Olympus has been honoured with numerous national and international design awards for its innovative product designs, including such prestigious awards as the Red Dot Award and the iF Award.

Olympus owns 17,000 patents across its product portfolio.



70%

### Global Market Share

Olympus is the leader in gastrointestinal endoscopic equipment.<sup>4</sup>



100

### Diseases or Conditions Treated

At Olympus we have versatile medical devices with the ability to treat approximately 100 diseases or conditions.<sup>5</sup>



11 Mio.

Approximately 11 million gastroscopies or colonoscopies performed with Olympus endoscopes per year are providing preventive healthcare to people throughout EMEA, or helping in the detection and treatment of disease.<sup>6</sup>

Colonoscopies, when carried out alongside immunological stool tests (FIT), are the most effective method for the early detection of colorectal cancer.<sup>7</sup>

OLYMPUS EUROPA SE & CO. KG Wendenstraße 20, 20097 Hamburg, [www.olympus-europa.com](http://www.olympus-europa.com)

Managing Directors: Carl Constantin Zangemeister (Executive Managing Director), Miquel-Àngel García, Marion Bönsch, Dr. Christian Meyer, Nacho Abia

Unless otherwise stated, the figures and information provided are as at the end of the financial year FY2022, in March 2022.

<sup>1</sup> Deviations from the total of 100% are due to rounding up and down.

<sup>2</sup> Other: e.g. Middle East and Africa.

<sup>3</sup> Clarivate Analytics (2019): Derwent Top 100 Global Innovators, available online at <https://clarivate.com/derwent/top100innovators/company/olympus/>

<sup>4</sup> As of November 2020.

<sup>5</sup> As of March 2021.

<sup>6</sup> Own projections.

<sup>7</sup> Lieberman D, Ladabaum U, Cruz-Correa M, et al. (2016): Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients: A Review. JAMA. 316(20):2135–2145. doi:10.1001/jama.2016.17418.

**CONTACT**